At a glance
| Trade context | Leuphasyl |
|---|---|
| Molecular size | Five amino acids |
| Proposed concept | Enkephalin-inspired signaling |
| Human evidence | Small or combination-formulation studies |
| Separate evidence tier | Computational interaction research |
Overview
Pentapeptide-18 is discussed as an enkephalin-inspired peptide intended for cosmetic modulation of expression-related lines. The commercial name Leuphasyl appears in older publications that use inconsistent peptide numbering, making identity checks important. Its evidence base includes a small volunteer formulation study, newer combinations with retinol, and molecular modeling. These study types answer different questions. A docking calculation does not measure wrinkle reduction, and a retinol-containing product can improve appearance without demonstrating that every added peptide contributes. Interpreting the evidence therefore requires knowing what was tested, rather than assuming that a mechanistic story guarantees a visible effect.
How it works
The proposed rationale involves modulation of neuronal signaling through an enkephalin-like concept, potentially reducing expression-related activity. This remains a cosmetic mechanistic hypothesis requiring evidence of relevant exposure in intact skin. A 2026 spectroscopic and computational study examined molecular properties and interactions; such work can generate hypotheses but cannot establish clinical neuromuscular inhibition, superiority to another treatment, or a durable cosmetic benefit.
The small early volunteer study
A 2014 report tested Leuphasyl-containing emulsions in twenty volunteers over two months and tracked facial lines with an imaging method. Its small size and lack of a clearly described matched placebo design limit causal interpretation. It provides preliminary product observations rather than robust evidence of isolated-peptide efficacy or equivalence to injected neuromodulators.
Supporting sources [1]
Combination and computational work
A 2024 study evaluated retinol and pentapeptide-18 in lipid-nanocarrier formulations. The delivery system and retinol are active parts of the intervention, so improvement cannot all be credited to the peptide. A 2026 structural and molecular-interaction paper supplies a different kind of evidence and should not be counted as another clinical wrinkle trial.
Keep the intended use and uncertainty clear
Cosmetic status is not FDA drug approval. Small volunteer studies cannot reliably detect rare reactions or define long-term exposure. Tolerability belongs to the finished product and delivery method, and topical research does not establish an injectable use or an anxiety, pain, or neurological indication.
Supporting sources [4]
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic enkephalin-inspired cosmetic pentapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Leuphasyl-containing emulsions: small cosmetic volunteer study ↗Clinical trial source · Checked 2026-10-27
- Retinol and pentapeptide-18 lipid-nanocarrier formulations ↗Original research · Checked 2026-10-27
- Pentapeptide-18: spectroscopic characterization and molecular-interaction analysis ↗Original research · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27